ID   SPYA_HUMAN              Reviewed;         392 AA.
AC   P21549; Q53QU6;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 1.
DT   10-MAY-2017, entry version 170.
DE   RecName: Full=Serine--pyruvate aminotransferase;
DE            Short=SPT;
DE            EC=2.6.1.51;
DE   AltName: Full=Alanine--glyoxylate aminotransferase;
DE            Short=AGT;
DE            EC=2.6.1.44;
GN   Name=AGXT; Synonyms=AGT1, SPAT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=2253628; DOI=10.1111/j.1432-1033.1990.tb19420.x;
RA   Nishiyama K., Berstein G., Oda T., Ichiyama A.;
RT   "Cloning and nucleotide sequence of cDNA encoding human liver serine-
RT   pyruvate aminotransferase.";
RL   Eur. J. Biochem. 194:9-18(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], VARIANTS LEU-11 AND MET-340, VARIANT HP1
RP   ARG-170, AND SUBCELLULAR LOCATION.
RX   PubMed=1703535; DOI=10.1083/jcb.111.6.2341;
RA   Purdue P.E., Takada Y., Danpure C.J.;
RT   "Identification of mutations associated with peroxisome-to-
RT   mitochondrion mistargeting of alanine/glyoxylate aminotransferase in
RT   primary hyperoxaluria type 1.";
RL   J. Cell Biol. 111:2341-2351(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2363689; DOI=10.1042/bj2680517;
RA   Takada Y., Kaneko N., Esumi H., Purdue P.E., Danpure C.J.;
RT   "Human peroxisomal L-alanine: glyoxylate aminotransferase.
RT   Evolutionary loss of a mitochondrial targeting signal by point
RT   mutation of the initiation codon.";
RL   Biochem. J. 268:517-520(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2045108; DOI=10.1016/0888-7543(91)90481-S;
RA   Purdue P.E., Lumb M.J., Fox M., Griffo G., Hamon-Benais C., Povey S.,
RA   Danpure C.J.;
RT   "Characterization and chromosomal mapping of a genomic clone encoding
RT   human alanine:glyoxylate aminotransferase.";
RL   Genomics 10:34-42(1991).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-9, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN COMPLEX WITH PYRIDOXAL
RP   PHOSPHATE AND AMINO-OXYACETIC ACID, SUBUNIT, AND PYRIDOXAL PHOSPHATE
RP   AT LYS-209.
RX   PubMed=12899834; DOI=10.1016/S0022-2836(03)00791-5;
RA   Zhang X., Roe S.M., Hou Y., Bartlam M., Rao Z., Pearl L.H.,
RA   Danpure C.J.;
RT   "Crystal structure of alanine:glyoxylate aminotransferase and the
RT   relationship between genotype and enzymatic phenotype in primary
RT   hyperoxaluria type 1.";
RL   J. Mol. Biol. 331:643-652(2003).
RN   [11]
RP   VARIANT HP1 PRO-205.
RX   PubMed=2039493; DOI=10.1016/0006-291X(91)90396-O;
RA   Nishiyama K., Funai T., Katafuchi R., Hattori F., Onoyama K.,
RA   Ichiyama A.;
RT   "Primary hyperoxaluria type I due to a point mutation of T to C in the
RT   coding region of the serine:pyruvate aminotransferase gene.";
RL   Biochem. Biophys. Res. Commun. 176:1093-1099(1991).
RN   [12]
RP   VARIANT HP1 GLU-82.
RX   PubMed=1349575; DOI=10.1016/0888-7543(92)90225-H;
RA   Purdue P.E., Lumb M.J., Allsop J., Minatogawa Y., Danpure C.J.;
RT   "A glycine-to-glutamate substitution abolishes alanine:glyoxylate
RT   aminotransferase catalytic activity in a subset of patients with
RT   primary hyperoxaluria type 1.";
RL   Genomics 13:215-218(1992).
RN   [13]
RP   VARIANT HP1 PHE-187.
RX   PubMed=1301173; DOI=10.1093/hmg/1.8.643;
RA   Minatogawa Y., Tone S., Allsop J., Purdue P.E., Takada Y.,
RA   Danpure C.J., Kido R.;
RT   "A serine-to-phenylalanine substitution leads to loss of
RT   alanine:glyoxylate aminotransferase catalytic activity and
RT   immunoreactivity in a patient with primary hyperoxaluria type 1.";
RL   Hum. Mol. Genet. 1:643-644(1992).
RN   [14]
RP   VARIANTS HP1 ARG-41 AND ILE-152.
RX   PubMed=8101040;
RA   Danpure C.J., Purdue P.E., Fryer P., Griffiths S., Allsop J.,
RA   Lumb M.J., Guttridge K.M., Jennings P.R., Scheinman J.I., Mauer S.M.,
RA   Davidson N.O.;
RT   "Enzymological and mutational analysis of a complex primary
RT   hyperoxaluria type 1 phenotype involving alanine:glyoxylate
RT   aminotransferase peroxisome-to-mitochondrion mistargeting and
RT   intraperoxisomal aggregation.";
RL   Am. J. Hum. Genet. 53:417-432(1993).
RN   [15]
RP   REVIEW ON HP1.
RX   PubMed=8507692; DOI=10.1016/0300-9084(93)90091-6;
RA   Danpure C.J.;
RT   "Primary hyperoxaluria type 1 and peroxisome-to-mitochondrion
RT   mistargeting of alanine:glyoxylate aminotransferase.";
RL   Biochimie 75:309-315(1993).
RN   [16]
RP   VARIANTS HP1 CYS-233; HIS-233 AND THR-244.
RX   PubMed=9192270; DOI=10.1136/jmg.34.6.489;
RA   von Schnakenburg C., Rumsby G.;
RT   "Primary hyperoxaluria type 1: a cluster of new mutations in exon 7 of
RT   the AGXT gene.";
RL   J. Med. Genet. 34:489-492(1997).
RN   [17]
RP   VARIANTS HP1 ARG-108; TYR-173; ARG-190; ALA-296 DEL AND ASP-350.
RX   PubMed=9604803;
RA   von Schnakenburg C., Rumsby G.;
RT   "Identification of new mutations in primary hyperoxaluria type 1
RT   (PH1).";
RL   J. Nephrol. 11:15-17(1998).
RN   [18]
RP   VARIANTS HP1 VAL-41; GLU-95 INS; ARG-116 AND ARG-156.
RX   PubMed=10394939; DOI=10.1007/s004390050984;
RA   Amoroso A., Pirulli D., Puzzer D., Ferri L., Crovella S.,
RA   Ferrettini C., Marangella M., Mazzola G., Florian F.;
RT   "Gene symbol: AGXT. Disease: primary hyperoxaluria type I.";
RL   Hum. Genet. 104:441-441(1999).
RN   [19]
RP   VARIANTS HP1 VAL-41; GLU-95 INS; ARG-116 AND ARG-156.
RX   PubMed=10453743; DOI=10.1007/s004390050998;
RA   Pirulli D., Puzzer D., Ferri L., Crovella S., Amoroso A.,
RA   Ferrettini C., Marangella M., Mazzola G., Florian F.;
RT   "Molecular analysis of hyperoxaluria type 1 in Italian patients
RT   reveals eight new mutations in the alanine: glyoxylate
RT   aminotransferase gene.";
RL   Hum. Genet. 104:523-525(1999).
RN   [20]
RP   VARIANTS HP1 ARG-41; ARG-156; ARG-190; THR-244; CYS-289 AND PRO-298.
RX   PubMed=10541294;
RA   Rinat C., Wanders R.J.A., Drukker A., Halle D., Frishberg Y.;
RT   "Primary hyperoxaluria type I: a model for multiple mutations in a
RT   monogenic disease within a distinct ethnic group.";
RL   J. Am. Soc. Nephrol. 10:2352-2358(1999).
RN   [21]
RP   VARIANTS HP1 ILE-152; ARG-170; ASN-183; CYS-233 AND THR-244.
RX   PubMed=10862087;
RX   DOI=10.1002/1098-1004(200006)15:6<577::AID-HUMU9>3.0.CO;2-#;
RA   Basmaison O., Rolland M.-O., Cochat P., Bozon D.;
RT   "Identification of 5 novel mutations in the AGXT gene.";
RL   Hum. Mutat. 15:577-577(2000).
RN   [22]
RP   CHARACTERIZATION OF VARIANTS HP1 ARG-41; GLU-82; ILE-152; ARG-170 AND
RP   THR-244, CHARACTERIZATION OF VARIANT LEU-11, AND MUTAGENESIS OF
RP   LYS-209.
RX   PubMed=10960483; DOI=10.1074/jbc.M006693200;
RA   Lumb M.J., Danpure C.J.;
RT   "Functional synergism between the most common polymorphism in human
RT   alanine:glyoxylate aminotransferase and four of the most common
RT   disease-causing mutations.";
RL   J. Biol. Chem. 275:36415-36422(2000).
RN   [23]
RP   VARIANT HP1 ASP-112, AND VARIANT ILE-326.
RX   PubMed=12559847; DOI=10.1016/S1096-7192(02)00204-4;
RA   Coulter-Mackie M.B., Tung A., Henderson H.E., Toone J.R.,
RA   Applegarth D.A.;
RT   "The AGT gene in Africa: a distinctive minor allele haplotype, a
RT   polymorphism (V326I), and a novel PH1 mutation (A112D) in Black
RT   Africans.";
RL   Mol. Genet. Metab. 78:44-50(2003).
RN   [24]
RP   CHARACTERIZATION OF VARIANT HP1 THR-244.
RX   PubMed=12777626; DOI=10.1073/pnas.1131968100;
RA   Santana A., Salido E., Torres A., Shapiro L.J.;
RT   "Primary hyperoxaluria type 1 in the Canary Islands: a conformational
RT   disease due to I244T mutation in the P11L-containing
RT   alanine:glyoxylate aminotransferase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:7277-7282(2003).
RN   [25]
RP   VARIANTS HP1 ARG-82; ILE-152; VAL-153; ARG-170 AND ASP-336.
RX   PubMed=15253729; DOI=10.1111/j.1523-1755.2004.00796.x;
RA   van Woerden C.S., Groothoff J.W., Wijburg F.A., Annink C.,
RA   Wanders R.J.A., Waterham H.R.;
RT   "Clinical implications of mutation analysis in primary hyperoxaluria
RT   type 1.";
RL   Kidney Int. 66:746-752(2004).
RN   [26]
RP   VARIANTS HP1 VAL-139 DEL; ARG-156; LEU-158; ARG-190; GLU-201; LEU-233;
RP   THR-244 AND ARG-253, AND VARIANT ASN-9.
RX   PubMed=15849466; DOI=10.1159/000085411;
RA   Monico C.G., Olson J.B., Milliner D.S.;
RT   "Implications of genotype and enzyme phenotype in pyridoxine response
RT   of patients with type I primary hyperoxaluria.";
RL   Am. J. Nephrol. 25:183-188(2005).
RN   [27]
RP   VARIANTS HP1 ARG-41; ARG-108; ARG-156; ARG-190; ARG-195; HIS-243;
RP   THR-244; MET-279; THR-287; CYS-289 AND PRO-298, AND VARIANT ASN-9.
RX   PubMed=15961946; DOI=10.1159/000086357;
RA   Frishberg Y., Rinat C., Shalata A., Khatib I., Feinstein S.,
RA   Becker-Cohen R., Weismann I., Wanders R.J.A., Rumsby G., Roels F.,
RA   Mandel H.;
RT   "Intra-familial clinical heterogeneity: absence of genotype-phenotype
RT   correlation in primary hyperoxaluria type 1 in Israel.";
RL   Am. J. Nephrol. 25:269-275(2005).
RN   [28]
RP   VARIANTS HP1 ARG-161 AND LEU-218, AND VARIANTS THR-279 AND VAL-280.
RX   PubMed=15963748; DOI=10.1016/j.ymgme.2005.05.005;
RA   Coulter-Mackie M.B., Lian Q., Applegarth D., Toone J.;
RT   "The major allele of the alanine:glyoxylate aminotransferase gene:
RT   nine novel mutations and polymorphisms associated with primary
RT   hyperoxaluria type 1.";
RL   Mol. Genet. Metab. 86:172-178(2005).
RN   [29]
RP   CHARACTERIZATION OF VARIANTS HP1 ARG-41; VAL-41; GLU-82; ARG-108;
RP   ASP-112; ARG-156; ARG-161; ARG-170; TYR-173; ASN-183; PHE-187; PRO-205
RP   AND LEU-218, MUTAGENESIS OF LYS-209, AND SUBUNIT.
RX   PubMed=16971151; DOI=10.1016/j.ymgme.2006.07.013;
RA   Coulter-Mackie M.B., Lian Q.;
RT   "Consequences of missense mutations for dimerization and turnover of
RT   alanine:glyoxylate aminotransferase: study of a spectrum of
RT   mutations.";
RL   Mol. Genet. Metab. 89:349-359(2006).
RN   [30]
RP   VARIANTS HP1 CYS-36; ARG-41; GLU-41; PRO-150; ILE-152; ARG-156;
RP   LEU-158; CYS-161; SER-161; PRO-166; ARG-170; TYR-173; CYS-233;
RP   HIS-233; THR-244 AND ARG-253, VARIANT ASN-9, CHARACTERIZATION OF
RP   VARIANTS HP1 CYS-36; GLU-41; PRO-150; ARG-156; LEU-158; CYS-161;
RP   SER-161; PRO-166; TYR-173; CYS-233; HIS-233 AND ARG-253, AND
RP   CHARACTERIZATION OF VARIANT ASN-9.
RX   PubMed=17495019; DOI=10.1373/clinchem.2006.084434;
RA   Williams E., Rumsby G.;
RT   "Selected exonic sequencing of the AGXT gene provides a genetic
RT   diagnosis in 50% of patients with primary hyperoxaluria type 1.";
RL   Clin. Chem. 53:1216-1221(2007).
RN   [31]
RP   CHARACTERIZATION OF VARIANTS HP1 ARG-161; CYS-161 AND SER-161, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=24055001; DOI=10.1016/j.bbadis.2013.09.002;
RA   Oppici E., Roncador A., Montioli R., Bianconi S., Cellini B.;
RT   "Gly161 mutations associated with primary hyperoxaluria type I induce
RT   the cytosolic aggregation and the intracellular degradation of the
RT   apo-form of alanine:glyoxylate aminotransferase.";
RL   Biochim. Biophys. Acta 1832:2277-2288(2013).
RN   [32]
RP   CHARACTERIZATION OF VARIANTS HP1 ARG-41; ILE-152; ARG-170 AND THR-244,
RP   SUBCELLULAR LOCATION, AND SUBUNIT.
RX   PubMed=23229545; DOI=10.1074/jbc.M112.432617;
RA   Fargue S., Lewin J., Rumsby G., Danpure C.J.;
RT   "Four of the most common mutations in primary hyperoxaluria type 1
RT   unmask the cryptic mitochondrial targeting sequence of
RT   alanine:glyoxylate aminotransferase encoded by the polymorphic minor
RT   allele.";
RL   J. Biol. Chem. 288:2475-2484(2013).
RN   [33]
RP   VARIANT HP1 ASN-202.
RX   PubMed=24934730; DOI=10.1186/1471-2369-15-92;
RA   Li G.M., Xu H., Shen Q., Gong Y.N., Fang X.Y., Sun L., Liu H.M.,
RA   An Y.;
RT   "Mutational analysis of AGXT in two Chinese families with primary
RT   hyperoxaluria type 1.";
RL   BMC Nephrol. 15:92-92(2014).
RN   [34]
RP   CHARACTERIZATION OF VARIANT HP1 ARG-47, AND SUBCELLULAR LOCATION.
RX   PubMed=26149463; DOI=10.1016/j.bbapap.2015.07.002;
RA   Montioli R., Oppici E., Dindo M., Roncador A., Gotte G., Cellini B.,
RA   Borri Voltattorni C.;
RT   "Misfolding caused by the pathogenic mutation G47R on the minor allele
RT   of alanine:glyoxylate aminotransferase and chaperoning activity of
RT   pyridoxine.";
RL   Biochim. Biophys. Acta 1854:1280-1289(2015).
CC   -!- CATALYTIC ACTIVITY: L-serine + pyruvate = 3-hydroxypyruvate + L-
CC       alanine.
CC   -!- CATALYTIC ACTIVITY: L-alanine + glyoxylate = pyruvate + glycine.
CC   -!- COFACTOR:
CC       Name=pyridoxal 5'-phosphate; Xref=ChEBI:CHEBI:597326;
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:12899834,
CC       ECO:0000269|PubMed:16971151, ECO:0000269|PubMed:23229545}.
CC   -!- SUBCELLULAR LOCATION: Peroxisome {ECO:0000269|PubMed:1703535,
CC       ECO:0000269|PubMed:23229545, ECO:0000269|PubMed:24055001,
CC       ECO:0000269|PubMed:26149463}. Mitochondrion
CC       {ECO:0000269|PubMed:1703535, ECO:0000269|PubMed:23229545}.
CC       Note=Predominantly localized in the peroxisomes. Mitochondrial
CC       mistargeting occurs in variant proteins Arg-41, Arg-47, Ile-152,
CC       Arg-170 and Thr-244 associated with the disease HP1.
CC       {ECO:0000269|PubMed:23229545}.
CC   -!- TISSUE SPECIFICITY: Liver.
CC   -!- POLYMORPHISM: Polymorphism at position 11 acts synergistically
CC       with different mutations in AGXT producing specific enzymic
CC       phenotypes in HP1 patients. The combined presence of Leu-11 and
CC       Met-340 polymorphisms defines the minor AGXT allele, whereas their
CC       absence defines the major allele. The minor allele has frequencies
CC       of 20% in normal European and North American populations, and 50%
CC       in HP1 patients. {ECO:0000269|PubMed:1703535}.
CC   -!- DISEASE: Hyperoxaluria primary 1 (HP1) [MIM:259900]: An inborn
CC       error of glyoxylate metabolism characterized by increased
CC       excretion of oxalate and glycolate, and progressive tissue
CC       accumulation of insoluble calcium oxalate. Affected individuals
CC       are at risk for nephrolithiasis, nephrocalcinosis and early onset
CC       end-stage renal disease. {ECO:0000269|PubMed:10394939,
CC       ECO:0000269|PubMed:10453743, ECO:0000269|PubMed:10541294,
CC       ECO:0000269|PubMed:10862087, ECO:0000269|PubMed:10960483,
CC       ECO:0000269|PubMed:12559847, ECO:0000269|PubMed:12777626,
CC       ECO:0000269|PubMed:1301173, ECO:0000269|PubMed:1349575,
CC       ECO:0000269|PubMed:15253729, ECO:0000269|PubMed:15849466,
CC       ECO:0000269|PubMed:15961946, ECO:0000269|PubMed:15963748,
CC       ECO:0000269|PubMed:16971151, ECO:0000269|PubMed:1703535,
CC       ECO:0000269|PubMed:17495019, ECO:0000269|PubMed:2039493,
CC       ECO:0000269|PubMed:23229545, ECO:0000269|PubMed:24055001,
CC       ECO:0000269|PubMed:24934730, ECO:0000269|PubMed:26149463,
CC       ECO:0000269|PubMed:8101040, ECO:0000269|PubMed:9192270,
CC       ECO:0000269|PubMed:9604803}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the class-V pyridoxal-phosphate-dependent
CC       aminotransferase family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X56092; CAA39572.1; -; mRNA.
DR   EMBL; X53414; CAA37493.1; -; mRNA.
DR   EMBL; D13368; BAA02632.1; -; mRNA.
DR   EMBL; M61763; AAA51680.1; -; Genomic_DNA.
DR   EMBL; AK292754; BAF85443.1; -; mRNA.
DR   EMBL; AC104809; AAY24168.1; -; Genomic_DNA.
DR   EMBL; CH471063; EAW71222.1; -; Genomic_DNA.
DR   EMBL; BC132819; AAI32820.1; -; mRNA.
DR   CCDS; CCDS2543.1; -.
DR   PIR; I39419; XNHUSP.
DR   RefSeq; NP_000021.1; NM_000030.2.
DR   UniGene; Hs.144567; -.
DR   PDB; 1H0C; X-ray; 2.50 A; A=1-392.
DR   PDB; 1J04; X-ray; 2.60 A; A=1-392.
DR   PDB; 2YOB; X-ray; 1.90 A; A/B=1-388.
DR   PDB; 3R9A; X-ray; 2.35 A; A/C=1-392.
DR   PDB; 4CBR; X-ray; 2.30 A; A=1-392.
DR   PDB; 4CBS; X-ray; 2.30 A; A=1-392.
DR   PDB; 4I8A; X-ray; 2.90 A; A/B/C/D=1-392.
DR   PDB; 4KXK; X-ray; 2.90 A; A/C=1-392.
DR   PDB; 4KYO; X-ray; 2.20 A; A/C=1-392.
DR   PDB; 5F9S; X-ray; 1.70 A; A/B=6-391.
DR   PDB; 5HHY; X-ray; 1.70 A; A/B=6-391.
DR   PDBsum; 1H0C; -.
DR   PDBsum; 1J04; -.
DR   PDBsum; 2YOB; -.
DR   PDBsum; 3R9A; -.
DR   PDBsum; 4CBR; -.
DR   PDBsum; 4CBS; -.
DR   PDBsum; 4I8A; -.
DR   PDBsum; 4KXK; -.
DR   PDBsum; 4KYO; -.
DR   PDBsum; 5F9S; -.
DR   PDBsum; 5HHY; -.
DR   ProteinModelPortal; P21549; -.
DR   SMR; P21549; -.
DR   BioGrid; 106694; 4.
DR   DIP; DIP-59650N; -.
DR   IntAct; P21549; 27.
DR   MINT; MINT-1419187; -.
DR   STRING; 9606.ENSP00000302620; -.
DR   DrugBank; DB08060; 4-(2-AMINOPHENYL)-4-OXOBUTANOIC ACID.
DR   DrugBank; DB02079; Aminooxyacetic acid.
DR   DrugBank; DB00145; Glycine.
DR   DrugBank; DB00160; L-Alanine.
DR   DrugBank; DB00133; L-Serine.
DR   DrugBank; DB04083; N'-Pyridoxyl-Lysine-5'-Monophosphate.
DR   DrugBank; DB00114; Pyridoxal Phosphate.
DR   iPTMnet; P21549; -.
DR   PhosphoSitePlus; P21549; -.
DR   BioMuta; AGXT; -.
DR   DMDM; 134855; -.
DR   MaxQB; P21549; -.
DR   PaxDb; P21549; -.
DR   PeptideAtlas; P21549; -.
DR   PRIDE; P21549; -.
DR   Ensembl; ENST00000307503; ENSP00000302620; ENSG00000172482.
DR   GeneID; 189; -.
DR   KEGG; hsa:189; -.
DR   UCSC; uc002waa.5; human.
DR   CTD; 189; -.
DR   DisGeNET; 189; -.
DR   GeneCards; AGXT; -.
DR   GeneReviews; AGXT; -.
DR   HGNC; HGNC:341; AGXT.
DR   HPA; HPA035370; -.
DR   HPA; HPA035371; -.
DR   MalaCards; AGXT; -.
DR   MIM; 259900; phenotype.
DR   MIM; 604285; gene.
DR   neXtProt; NX_P21549; -.
DR   OpenTargets; ENSG00000172482; -.
DR   Orphanet; 93598; Primary hyperoxaluria type 1.
DR   PharmGKB; PA24633; -.
DR   eggNOG; KOG2862; Eukaryota.
DR   eggNOG; COG0075; LUCA.
DR   GeneTree; ENSGT00390000006648; -.
DR   HOGENOM; HOG000171815; -.
DR   HOVERGEN; HBG006907; -.
DR   InParanoid; P21549; -.
DR   KO; K00830; -.
DR   OMA; AYSCSQK; -.
DR   OrthoDB; EOG091G0EMK; -.
DR   PhylomeDB; P21549; -.
DR   TreeFam; TF313234; -.
DR   BioCyc; MetaCyc:HS10525-MONOMER; -.
DR   BRENDA; 2.6.1.44; 2681.
DR   Reactome; R-HSA-389661; Glyoxylate metabolism and glycine degradation.
DR   EvolutionaryTrace; P21549; -.
DR   GeneWiki; AGXT; -.
DR   GenomeRNAi; 189; -.
DR   PRO; PR:P21549; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000172482; -.
DR   CleanEx; HS_AGXT; -.
DR   Genevisible; P21549; HS.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:Ensembl.
DR   GO; GO:0005782; C:peroxisomal matrix; IDA:UniProtKB.
DR   GO; GO:0005777; C:peroxisome; IDA:UniProtKB.
DR   GO; GO:0008453; F:alanine-glyoxylate transaminase activity; IDA:UniProtKB.
DR   GO; GO:0016597; F:amino acid binding; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0043621; F:protein self-association; IDA:UniProtKB.
DR   GO; GO:0030170; F:pyridoxal phosphate binding; IDA:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IPI:UniProtKB.
DR   GO; GO:0004760; F:serine-pyruvate transaminase activity; IBA:GO_Central.
DR   GO; GO:0008483; F:transaminase activity; IDA:UniProtKB.
DR   GO; GO:0019265; P:glycine biosynthetic process, by transamination of glyoxylate; IDA:UniProtKB.
DR   GO; GO:0009436; P:glyoxylate catabolic process; IDA:UniProtKB.
DR   GO; GO:0046487; P:glyoxylate metabolic process; IMP:HGNC.
DR   GO; GO:0042853; P:L-alanine catabolic process; IDA:UniProtKB.
DR   GO; GO:0019448; P:L-cysteine catabolic process; IDA:UniProtKB.
DR   GO; GO:0007219; P:Notch signaling pathway; IEA:Ensembl.
DR   GO; GO:0046724; P:oxalic acid secretion; IEA:Ensembl.
DR   GO; GO:0042866; P:pyruvate biosynthetic process; IEA:Ensembl.
DR   GO; GO:0051591; P:response to cAMP; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   Gene3D; 3.40.640.10; -; 1.
DR   Gene3D; 3.90.1150.10; -; 1.
DR   InterPro; IPR000192; Aminotrans_V_dom.
DR   InterPro; IPR020578; Aminotrans_V_PyrdxlP_BS.
DR   InterPro; IPR015424; PyrdxlP-dep_Trfase.
DR   InterPro; IPR015421; PyrdxlP-dep_Trfase_major_sub1.
DR   InterPro; IPR015422; PyrdxlP-dep_Trfase_sub2.
DR   InterPro; IPR024169; SP_NH2Trfase/AEP_transaminase.
DR   Pfam; PF00266; Aminotran_5; 1.
DR   PIRSF; PIRSF000524; SPT; 1.
DR   SUPFAM; SSF53383; SSF53383; 1.
DR   PROSITE; PS00595; AA_TRANSFER_CLASS_5; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Aminotransferase; Complete proteome;
KW   Disease mutation; Mitochondrion; Peroxisome; Phosphoprotein;
KW   Polymorphism; Pyridoxal phosphate; Reference proteome; Transferase.
FT   CHAIN         1    392       Serine--pyruvate aminotransferase.
FT                                /FTId=PRO_0000150237.
FT   BINDING     360    360       Substrate.
FT   MOD_RES       9      9       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     209    209       N6-(pyridoxal phosphate)lysine.
FT   MOD_RES     225    225       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:O35423}.
FT   MOD_RES     225    225       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:O35423}.
FT   MOD_RES     234    234       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:O35423}.
FT   MOD_RES     312    312       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:O35423}.
FT   VARIANT       9      9       T -> N (polymorphism; no loss of
FT                                alanine--glyoxylate aminotransferase
FT                                activity; dbSNP:rs115014558).
FT                                {ECO:0000269|PubMed:15849466,
FT                                ECO:0000269|PubMed:15961946,
FT                                ECO:0000269|PubMed:17495019}.
FT                                /FTId=VAR_060547.
FT   VARIANT      11     11       P -> L (common polymorphism; reduction of
FT                                specific alanine--glyoxylate
FT                                aminotransferase activity in vitro;
FT                                causes mitochondrial mistargeting when
FT                                associated with R-170; dbSNP:rs34116584).
FT                                {ECO:0000269|PubMed:10960483,
FT                                ECO:0000269|PubMed:1703535}.
FT                                /FTId=VAR_000587.
FT   VARIANT      22     22       N -> S (in dbSNP:rs34885252).
FT                                /FTId=VAR_048236.
FT   VARIANT      36     36       R -> C (in HP1; when associated with L-11
FT                                and M-340 on the minor AGXT allele;
FT                                results in loss of alanine--glyoxylate
FT                                aminotransferase activity;
FT                                dbSNP:rs180177157).
FT                                {ECO:0000269|PubMed:17495019}.
FT                                /FTId=VAR_074582.
FT   VARIANT      41     41       G -> E (in HP1; loss of alanine--
FT                                glyoxylate aminotransferase activity;
FT                                dbSNP:rs180177168).
FT                                {ECO:0000269|PubMed:17495019}.
FT                                /FTId=VAR_074583.
FT   VARIANT      41     41       G -> R (in HP1; when associated with L-11
FT                                and M-340 on the minor AGXT allele;
FT                                results in loss of protein stability;
FT                                loss of alanine--glyoxylate
FT                                aminotransferase activity; loss of
FT                                dimerization; partial mitochondrial
FT                                mistargeting; intraperoxisomal protein
FT                                aggregation seen; dbSNP:rs121908523).
FT                                {ECO:0000269|PubMed:10541294,
FT                                ECO:0000269|PubMed:10960483,
FT                                ECO:0000269|PubMed:15961946,
FT                                ECO:0000269|PubMed:16971151,
FT                                ECO:0000269|PubMed:17495019,
FT                                ECO:0000269|PubMed:23229545,
FT                                ECO:0000269|PubMed:8101040}.
FT                                /FTId=VAR_000588.
FT   VARIANT      41     41       G -> V (in HP1; reduced alanine--
FT                                glyoxylate aminotransferase activity; no
FT                                loss of dimerization; no effect on
FT                                protein stability; dbSNP:rs180177168).
FT                                {ECO:0000269|PubMed:10394939,
FT                                ECO:0000269|PubMed:10453743,
FT                                ECO:0000269|PubMed:16971151}.
FT                                /FTId=VAR_010969.
FT   VARIANT      47     47       G -> R (in HP1; when associated with L-11
FT                                and M-340 on the minor AGXT allele;
FT                                results in protein misfolding; decreased
FT                                alanine--glyoxylate aminotransferase
FT                                activity; reduced expression levels;
FT                                reduced pyridoxal phosphate binding;
FT                                reduced dimerization; reduced
FT                                thermostability; increased propensity to
FT                                aggregation; increased susceptibility to
FT                                proteolytic degradation within the N-
FT                                terminal region; mitochondrial
FT                                mistargeting; exposure to pyridoxine can
FT                                rescue the functionality by partially
FT                                preventing aggregation and degradation
FT                                and by redirecting all the protein to the
FT                                peroxisome; dbSNP:rs180177173).
FT                                {ECO:0000269|PubMed:26149463}.
FT                                /FTId=VAR_074584.
FT   VARIANT      82     82       G -> E (in HP1; abolishes alanine--
FT                                glyoxylate aminotransferase activity by
FT                                interfering with pyridoxal phosphate
FT                                binding; dbSNP:rs121908522).
FT                                {ECO:0000269|PubMed:10960483,
FT                                ECO:0000269|PubMed:1349575,
FT                                ECO:0000269|PubMed:16971151}.
FT                                /FTId=VAR_008878.
FT   VARIANT      82     82       G -> R (in HP1; dbSNP:rs180177185).
FT                                {ECO:0000269|PubMed:15253729}.
FT                                /FTId=VAR_060548.
FT   VARIANT      95     95       E -> EE (in HP1).
FT                                {ECO:0000269|PubMed:10394939,
FT                                ECO:0000269|PubMed:10453743}.
FT                                /FTId=VAR_010970.
FT   VARIANT     108    108       W -> R (in HP1; when associated with L-11
FT                                and M-340 on the minor AGXT allele;
FT                                results in loss of alanine--glyoxylate
FT                                aminotransferase activity; loss of
FT                                dimerization; decreased protein
FT                                stability; dbSNP:rs180177197).
FT                                {ECO:0000269|PubMed:15961946,
FT                                ECO:0000269|PubMed:16971151,
FT                                ECO:0000269|PubMed:9604803}.
FT                                /FTId=VAR_060549.
FT   VARIANT     112    112       A -> D (in HP1; loss of alanine--
FT                                glyoxylate aminotransferase activity;
FT                                loss of dimerization; decreased protein
FT                                stability; causes protein aggregation;
FT                                dbSNP:rs796052061).
FT                                {ECO:0000269|PubMed:12559847,
FT                                ECO:0000269|PubMed:16971151}.
FT                                /FTId=VAR_060550.
FT   VARIANT     116    116       G -> R (in HP1; dbSNP:rs180177207).
FT                                {ECO:0000269|PubMed:10394939,
FT                                ECO:0000269|PubMed:10453743}.
FT                                /FTId=VAR_010971.
FT   VARIANT     139    139       Missing (in HP1).
FT                                {ECO:0000269|PubMed:15849466}.
FT                                /FTId=VAR_060551.
FT   VARIANT     150    150       L -> P (in HP1; when associated with L-11
FT                                and M-340 on the minor AGXT allele;
FT                                results in loss of alanine--glyoxylate
FT                                aminotransferase activity;
FT                                dbSNP:rs180177222).
FT                                {ECO:0000269|PubMed:17495019}.
FT                                /FTId=VAR_074585.
FT   VARIANT     152    152       F -> I (in HP1; when associated with L-11
FT                                and M-340 on the minor AGXT allele;
FT                                results in protein destabilization;
FT                                decreased alanine--glyoxylate
FT                                aminotransferase activity; no loss of
FT                                dimerization; mitochondrial mistargeting;
FT                                dbSNP:rs121908524).
FT                                {ECO:0000269|PubMed:10862087,
FT                                ECO:0000269|PubMed:10960483,
FT                                ECO:0000269|PubMed:15253729,
FT                                ECO:0000269|PubMed:17495019,
FT                                ECO:0000269|PubMed:23229545,
FT                                ECO:0000269|PubMed:8101040}.
FT                                /FTId=VAR_000589.
FT   VARIANT     153    153       L -> V (in HP1; dbSNP:rs180177223).
FT                                {ECO:0000269|PubMed:15253729}.
FT                                /FTId=VAR_060552.
FT   VARIANT     156    156       G -> R (in HP1; loss of alanine--
FT                                glyoxylate aminotransferase activity;
FT                                loss of dimerization; decreased protein
FT                                stability; dbSNP:rs121908530).
FT                                {ECO:0000269|PubMed:10394939,
FT                                ECO:0000269|PubMed:10453743,
FT                                ECO:0000269|PubMed:10541294,
FT                                ECO:0000269|PubMed:15849466,
FT                                ECO:0000269|PubMed:15961946,
FT                                ECO:0000269|PubMed:16971151,
FT                                ECO:0000269|PubMed:17495019}.
FT                                /FTId=VAR_010972.
FT   VARIANT     158    158       S -> L (in HP1; loss of alanine--
FT                                glyoxylate aminotransferase activity;
FT                                dbSNP:rs180177225).
FT                                {ECO:0000269|PubMed:15849466,
FT                                ECO:0000269|PubMed:17495019}.
FT                                /FTId=VAR_060553.
FT   VARIANT     161    161       G -> C (in HP1; when associated with L-11
FT                                and M-340 on the minor AGXT allele;
FT                                results in loss of alanine--glyoxylate
FT                                aminotransferase activity; reduced
FT                                expression levels; decreased protein
FT                                stability; protein aggregation seen in
FT                                the cytosol with a decreased aggregation
FT                                propensity in the presence of pyridoxal
FT                                phosphate; reduced peroxisomal
FT                                localization; dbSNP:rs180177227).
FT                                {ECO:0000269|PubMed:17495019,
FT                                ECO:0000269|PubMed:24055001}.
FT                                /FTId=VAR_074586.
FT   VARIANT     161    161       G -> R (in HP1; loss of alanine--
FT                                glyoxylate aminotransferase activity;
FT                                reduced expression levels; decreased
FT                                protein stability; protein aggregation
FT                                seen in the cytosol with a decreased
FT                                aggregation propensity in the presence of
FT                                pyridoxal phosphate; loss of
FT                                dimerization; dbSNP:rs180177227).
FT                                {ECO:0000269|PubMed:15963748,
FT                                ECO:0000269|PubMed:16971151,
FT                                ECO:0000269|PubMed:24055001}.
FT                                /FTId=VAR_060554.
FT   VARIANT     161    161       G -> S (in HP1; when associated with L-11
FT                                and M-340 on the minor AGXT allele;
FT                                results in loss of alanine--glyoxylate
FT                                aminotransferase activity; reduced
FT                                expression levels; decreased protein
FT                                stability; protein aggregation seen in
FT                                the cytosol with a decreased aggregation
FT                                propensity in the presence of pyridoxal
FT                                phosphate; reduced peroxisomal
FT                                localization; dbSNP:rs180177227).
FT                                {ECO:0000269|PubMed:17495019,
FT                                ECO:0000269|PubMed:24055001}.
FT                                /FTId=VAR_074587.
FT   VARIANT     166    166       L -> P (in HP1; when associated with L-11
FT                                and M-340 on the minor AGXT allele;
FT                                results in loss of alanine--glyoxylate
FT                                aminotransferase activity;
FT                                dbSNP:rs180177230).
FT                                {ECO:0000269|PubMed:17495019}.
FT                                /FTId=VAR_074588.
FT   VARIANT     170    170       G -> R (in HP1; when associated with L-11
FT                                and M-340 on the minor AGXT allele;
FT                                results in mitochondrial mistargeting;
FT                                slight decrease in alanine--glyoxylate
FT                                aminotransferase activity; loss of
FT                                dimerization; partial loss of protein
FT                                stability but protein stability increases
FT                                in the presence of pyridoxal phosphate;
FT                                causes protein aggregation;
FT                                dbSNP:rs121908529).
FT                                {ECO:0000269|PubMed:10862087,
FT                                ECO:0000269|PubMed:10960483,
FT                                ECO:0000269|PubMed:15253729,
FT                                ECO:0000269|PubMed:16971151,
FT                                ECO:0000269|PubMed:1703535,
FT                                ECO:0000269|PubMed:17495019,
FT                                ECO:0000269|PubMed:23229545}.
FT                                /FTId=VAR_000590.
FT   VARIANT     173    173       C -> Y (in HP1; loss of alanine--
FT                                glyoxylate aminotransferase activity;
FT                                loss of dimerization; decreased protein
FT                                stability; causes protein aggregation;
FT                                dbSNP:rs180177231).
FT                                {ECO:0000269|PubMed:16971151,
FT                                ECO:0000269|PubMed:17495019,
FT                                ECO:0000269|PubMed:9604803}.
FT                                /FTId=VAR_060555.
FT   VARIANT     183    183       D -> N (in HP1; loss of alanine--
FT                                glyoxylate aminotransferase activity; no
FT                                loss of dimerization; no effect on
FT                                protein stability; dbSNP:rs180177236).
FT                                {ECO:0000269|PubMed:10862087,
FT                                ECO:0000269|PubMed:16971151}.
FT                                /FTId=VAR_010973.
FT   VARIANT     187    187       S -> F (in HP1; loss of alanine--
FT                                glyoxylate aminotransferase activity;
FT                                loss of dimerization but improved
FT                                dimerization in the presence of pyridoxal
FT                                phosphate; decreased protein stability;
FT                                dbSNP:rs180177238).
FT                                {ECO:0000269|PubMed:1301173,
FT                                ECO:0000269|PubMed:16971151}.
FT                                /FTId=VAR_000591.
FT   VARIANT     190    190       G -> R (in HP1; dbSNP:rs180177239).
FT                                {ECO:0000269|PubMed:10541294,
FT                                ECO:0000269|PubMed:15849466,
FT                                ECO:0000269|PubMed:15961946,
FT                                ECO:0000269|PubMed:9604803}.
FT                                /FTId=VAR_060556.
FT   VARIANT     195    195       M -> R (in HP1; dbSNP:rs180177244).
FT                                {ECO:0000269|PubMed:15961946}.
FT                                /FTId=VAR_060557.
FT   VARIANT     201    201       D -> E (in HP1; dbSNP:rs180177246).
FT                                {ECO:0000269|PubMed:15849466}.
FT                                /FTId=VAR_060558.
FT   VARIANT     202    202       I -> N (in HP1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:24934730}.
FT                                /FTId=VAR_074589.
FT   VARIANT     205    205       S -> P (in HP1; loss of alanine--
FT                                glyoxylate aminotransferase activity;
FT                                decreased protein stability;
FT                                dbSNP:rs121908520).
FT                                {ECO:0000269|PubMed:16971151,
FT                                ECO:0000269|PubMed:2039493}.
FT                                /FTId=VAR_000592.
FT   VARIANT     218    218       S -> L (in HP1; loss of alanine--
FT                                glyoxylate aminotransferase activity;
FT                                loss of dimerization; no effect on
FT                                protein stability; dbSNP:rs180177253).
FT                                {ECO:0000269|PubMed:15963748,
FT                                ECO:0000269|PubMed:16971151}.
FT                                /FTId=VAR_060559.
FT   VARIANT     233    233       R -> C (in HP1; when associated with L-11
FT                                and M-340 on the minor AGXT allele;
FT                                results in loss of alanine--glyoxylate
FT                                aminotransferase activity;
FT                                dbSNP:rs121908526).
FT                                {ECO:0000269|PubMed:10862087,
FT                                ECO:0000269|PubMed:17495019,
FT                                ECO:0000269|PubMed:9192270}.
FT                                /FTId=VAR_008879.
FT   VARIANT     233    233       R -> H (in HP1; when associated with L-11
FT                                and M-340 on the minor AGXT allele;
FT                                results in loss of alanine--glyoxylate
FT                                aminotransferase activity;
FT                                dbSNP:rs121908527).
FT                                {ECO:0000269|PubMed:17495019,
FT                                ECO:0000269|PubMed:9192270}.
FT                                /FTId=VAR_008880.
FT   VARIANT     233    233       R -> L (in HP1; dbSNP:rs121908527).
FT                                {ECO:0000269|PubMed:15849466}.
FT                                /FTId=VAR_060560.
FT   VARIANT     243    243       D -> H (in HP1; dbSNP:rs180177258).
FT                                {ECO:0000269|PubMed:15961946}.
FT                                /FTId=VAR_060561.
FT   VARIANT     244    244       I -> T (in HP1; prevalent mutation in the
FT                                Canary islands; when associated with L-11
FT                                and M-340 on the minor AGXT allele;
FT                                results in protein misfolding; decreased
FT                                alanine--glyoxylate aminotransferase
FT                                activity; no loss of dimerization;
FT                                partial mitochondrial mistargeting;
FT                                dbSNP:rs121908525).
FT                                {ECO:0000269|PubMed:10541294,
FT                                ECO:0000269|PubMed:10862087,
FT                                ECO:0000269|PubMed:10960483,
FT                                ECO:0000269|PubMed:12777626,
FT                                ECO:0000269|PubMed:15849466,
FT                                ECO:0000269|PubMed:15961946,
FT                                ECO:0000269|PubMed:17495019,
FT                                ECO:0000269|PubMed:23229545,
FT                                ECO:0000269|PubMed:9192270}.
FT                                /FTId=VAR_008881.
FT   VARIANT     253    253       C -> R (in HP1; when associated with L-11
FT                                and M-340 on the minor AGXT allele;
FT                                results in loss of alanine--glyoxylate
FT                                aminotransferase activity;
FT                                dbSNP:rs180177264).
FT                                {ECO:0000269|PubMed:15849466,
FT                                ECO:0000269|PubMed:17495019}.
FT                                /FTId=VAR_060562.
FT   VARIANT     279    279       I -> M (in HP1; dbSNP:rs180177277).
FT                                {ECO:0000269|PubMed:15961946}.
FT                                /FTId=VAR_060563.
FT   VARIANT     279    279       I -> T (in dbSNP:rs140992177).
FT                                {ECO:0000269|PubMed:15963748}.
FT                                /FTId=VAR_060564.
FT   VARIANT     280    280       A -> V (in dbSNP:rs73106685).
FT                                {ECO:0000269|PubMed:15963748}.
FT                                /FTId=VAR_060565.
FT   VARIANT     287    287       S -> T (in HP1; dbSNP:rs180177289).
FT                                {ECO:0000269|PubMed:15961946}.
FT                                /FTId=VAR_060566.
FT   VARIANT     289    289       R -> C (in HP1; dbSNP:rs180177290).
FT                                {ECO:0000269|PubMed:10541294,
FT                                ECO:0000269|PubMed:15961946}.
FT                                /FTId=VAR_060567.
FT   VARIANT     295    295       A -> T (in dbSNP:rs13408961).
FT                                /FTId=VAR_048237.
FT   VARIANT     296    296       Missing (in HP1).
FT                                {ECO:0000269|PubMed:9604803}.
FT                                /FTId=VAR_060568.
FT   VARIANT     298    298       L -> P (in HP1; dbSNP:rs180177293).
FT                                {ECO:0000269|PubMed:10541294,
FT                                ECO:0000269|PubMed:15961946}.
FT                                /FTId=VAR_060569.
FT   VARIANT     326    326       V -> I (in dbSNP:rs115057148).
FT                                {ECO:0000269|PubMed:12559847}.
FT                                /FTId=VAR_060570.
FT   VARIANT     336    336       V -> D (in HP1; dbSNP:rs180177155).
FT                                {ECO:0000269|PubMed:15253729}.
FT                                /FTId=VAR_060571.
FT   VARIANT     340    340       I -> M (common polymorphism; associated
FT                                with hyperoxaluria; dbSNP:rs4426527).
FT                                {ECO:0000269|PubMed:1703535}.
FT                                /FTId=VAR_000593.
FT   VARIANT     350    350       G -> D (in HP1; dbSNP:rs180177156).
FT                                {ECO:0000269|PubMed:9604803}.
FT                                /FTId=VAR_060572.
FT   MUTAGEN     209    209       K->R: Affects pyridoxal phosphate
FT                                binding; loss of alanine--glyoxylate
FT                                aminotransferase activity.
FT                                {ECO:0000269|PubMed:10960483,
FT                                ECO:0000269|PubMed:16971151}.
FT   HELIX        13     15       {ECO:0000244|PDB:5F9S}.
FT   STRAND       27     29       {ECO:0000244|PDB:5F9S}.
FT   HELIX        35     41       {ECO:0000244|PDB:5F9S}.
FT   HELIX        51     68       {ECO:0000244|PDB:5F9S}.
FT   STRAND       73     80       {ECO:0000244|PDB:5F9S}.
FT   HELIX        82     93       {ECO:0000244|PDB:5F9S}.
FT   STRAND       99    106       {ECO:0000244|PDB:5F9S}.
FT   HELIX       107    118       {ECO:0000244|PDB:5F9S}.
FT   STRAND      122    127       {ECO:0000244|PDB:5F9S}.
FT   HELIX       136    146       {ECO:0000244|PDB:5F9S}.
FT   STRAND      149    156       {ECO:0000244|PDB:5F9S}.
FT   TURN        158    160       {ECO:0000244|PDB:5F9S}.
FT   HELIX       169    175       {ECO:0000244|PDB:5F9S}.
FT   STRAND      179    183       {ECO:0000244|PDB:5F9S}.
FT   TURN        185    190       {ECO:0000244|PDB:5F9S}.
FT   TURN        195    199       {ECO:0000244|PDB:5F9S}.
FT   STRAND      201    209       {ECO:0000244|PDB:5F9S}.
FT   STRAND      218    222       {ECO:0000244|PDB:5F9S}.
FT   HELIX       224    231       {ECO:0000244|PDB:5F9S}.
FT   HELIX       244    250       {ECO:0000244|PDB:5F9S}.
FT   STRAND      254    256       {ECO:0000244|PDB:5F9S}.
FT   HELIX       266    282       {ECO:0000244|PDB:5F9S}.
FT   HELIX       284    304       {ECO:0000244|PDB:5F9S}.
FT   STRAND      308    311       {ECO:0000244|PDB:5F9S}.
FT   HELIX       314    316       {ECO:0000244|PDB:5F9S}.
FT   STRAND      321    325       {ECO:0000244|PDB:5F9S}.
FT   HELIX       332    343       {ECO:0000244|PDB:5F9S}.
FT   STRAND      344    346       {ECO:0000244|PDB:4KYO}.
FT   HELIX       352    354       {ECO:0000244|PDB:5F9S}.
FT   TURN        355    357       {ECO:0000244|PDB:5F9S}.
FT   STRAND      358    362       {ECO:0000244|PDB:5F9S}.
FT   HELIX       365    367       {ECO:0000244|PDB:5F9S}.
FT   HELIX       370    386       {ECO:0000244|PDB:5F9S}.
SQ   SEQUENCE   392 AA;  43010 MW;  2987DDE85B2470B4 CRC64;
     MASHKLLVTP PKALLKPLSI PNQLLLGPGP SNLPPRIMAA GGLQMIGSMS KDMYQIMDEI
     KEGIQYVFQT RNPLTLVISG SGHCALEAAL VNVLEPGDSF LVGANGIWGQ RAVDIGERIG
     ARVHPMTKDP GGHYTLQEVE EGLAQHKPVL LFLTHGESST GVLQPLDGFG ELCHRYKCLL
     LVDSVASLGG TPLYMDRQGI DILYSGSQKA LNAPPGTSLI SFSDKAKKKM YSRKTKPFSF
     YLDIKWLANF WGCDDQPRMY HHTIPVISLY SLRESLALIA EQGLENSWRQ HREAAAYLHG
     RLQALGLQLF VKDPALRLPT VTTVAVPAGY DWRDIVSYVI DHFDIEIMGG LGPSTGKVLR
     IGLLGCNATR ENVDRVTEAL RAALQHCPKK KL
//
